Actively Recruiting
Cannabidiol for Reducing Cigarette Use
Led by University of California, Los Angeles · Updated on 2026-04-13
120
Participants Needed
1
Research Sites
113 weeks
Total Duration
On this page
Sponsors
U
University of California, Los Angeles
Lead Sponsor
C
Center For Medicinal Cannabis Research at UC San Diego Health
Collaborating Sponsor
AI-Summary
What this Trial Is About
The goal of this research is to evaluate the efficacy of cannabidiol (CBD) in reducing cigarette smoking. Although there are safe and effective treatments for smoking cessation, not everyone who attempts smoking cessation is successful, even with these treatments. Relapse rates are high, leaving a need for new approaches. Despite justification to evaluate CBD for this indication, human research on the topic is scant. Larger, more extended studies are warranted and essential. The investigators will recruit participants from CRI-Help, Inc., a substance abuse treatment program in North Hollywood, where residents who indicate the desire to stop smoking are prohibited from using other cannabis products which would affect recruitment. The aims of this study are: 1. Evaluate the effects of CBD on nicotine intake. 2. Exploratory Aims. Measure plasma concentrations of CBD, N-arachidonoyl-ethanolamine (anandamide) and 2-arachidonoylglycerol (2-AG) at baseline and day 7. Participants who meet eligibility criteria will take part in a 56-day treatment phase during which they receive the study medication under supervision (CBD or placebo twice daily) and complete questionnaires on side effects, withdrawal, craving and mood symptoms. Blood, breath, and urine tests will also be performed throughout the study. Participants who complete the treatment will also be assessed at 1-month and 3-month follow up visits.
CONDITIONS
Official Title
Cannabidiol for Reducing Cigarette Use
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Adults aged 18 to 65 years
- Diagnosed with Tobacco Use Disorder and wanting to quit smoking
- Smoking at least 5 cigarettes per day or scoring 4 or higher on the Fagerstr�f6m Test for Nicotine Dependence
- Recruited from Cri-Help Treatment Center where cannabis use is prohibited
- Equal numbers of males and females included
- Participants of all racial and ethnic groups included
- Not currently using nicotine vaping products
You will not qualify if you...
- Physiological dependence on alcohol or drugs requiring detox or showing acute withdrawal symptoms
- Receiving treatment for opioid use disorder with buprenorphine or methadone
- Diagnosed with schizophrenia, Bipolar I disorder, psychotic disorder, or active suicidal ideation/attempt in past 12 months
- Having AIDS or current HIV treatment
- Significant abnormalities on EKG or serious cardiovascular, hematologic, hepatic, renal, neurological, or endocrine issues
- Elevated liver enzymes or blood clotting abnormalities
- Pregnant or breastfeeding; contraception required during study
- Abnormal ovarian function based on hormone tests and ultrasound
- Taking medications that strongly induce or inhibit specific liver enzymes affecting CBD levels
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
CRI-Help, Inc.
North Hollywood, California, United States, 91601
Actively Recruiting
Research Team
E
Edythe D London, PhD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here